【摘要】 糖胺聚糖广泛应用于化妆品和保健品领域以及血栓、骨关节炎、癌症等临床医疗.目前,商品化糖胺聚糖依赖于动物组织提取,产品存在均一性差、有潜在致病因子等缺点.采用合成生物学策略合成糖胺聚糖及其寡糖可避免上述问题,且可实现精准控制硫酸化程度及产品分子量分布.随着基因组学和合成生物学的发展,透明质酸、软骨素、肝素前体、硫酸软骨素及肝素等的合成途径被阐释,多种平台菌株的遗传操作体系不断完善.基于合成生物学策略构建微生物细胞工厂合成糖胺聚糖已成为未来发展趋势.本文主要综述了近年来生产糖胺聚糖及其寡聚糖的生物策略尤其是相关合成生物学手段,以期为未来研究提供新思路.更多还原

【Abstract】 Glycosaminoglycans(GAGs) are widely used in cosmetics, health care and clinical treatments of thrombosis, osteoarthritis and cancer. Commercial GAGs largely depend on extraction from animal tissues. However, the products have poor homogeneity and carry potential pathogenic factors. Synthetic biology strategies for production GAGs and its oligosaccharides can avoid the above problems,and achieve precise control of the sulfation degree and molecular weights of GAG. With the development of genomics and synthetic biology, the biosynthesis pathways of hyaluronan, chondroitin, heparin, chondroitin sulfate and heparin have been elucidated, and many genetic operation systems for platform strains have also been continuously improved. Construction of microbial cell factories for producing GAGs has been considered as main development trends. This review summarized and discussed the recent biological strategies for the production of GAGs and their oligosaccharides, and provided new ideas for near future studies.更多还原